Aram Andrew Mangasarian
Director Ejecutivo en TME PHARMA N.V. .
Perfil
Aram Andrew Mangasarian is currently the Chief Executive Officer & Non-Executive Director at NOXXON Pharma AG since 2015.
He is also the Chief Executive Officer at TME Pharma NV since 2015.
Additionally, he holds the position of Director at NOXXON Pharma NV Niederlassung Deutschland.
Previously, he worked as a Director at Caerus Consulting AS.
From 2020 to 2023, he served as an Independent Director at Isofol Medical AB.
He was the Vice President-Development Affairs at Novexel SA from 2005 to 2012.
He also worked as a Manager at Exonhit from 2000 to 2012 and as the Vice President-Business Development at Eurobio-Scientific SA. Dr. Mangasarian completed his undergraduate degree at the University of Wisconsin.
He holds an MBA from INSEAD and a doctorate from the University of California San Diego.
Cargos activos de Aram Andrew Mangasarian
Empresas | Cargo | Inicio |
---|---|---|
TME PHARMA N.V. | Director Ejecutivo | 01/05/2010 |
NOXXON Pharma AG
NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | Director Ejecutivo | 01/05/2010 |
NOXXON Pharma NV Niederlassung Deutschland
NOXXON Pharma NV Niederlassung Deutschland BiotechnologyHealth Technology NOXXON Pharma NV Niederlassung Deutschland operates as a German biotechnology company. The private company is based in Berlin, Germany. | Director/Miembro de la Junta | - |
Antiguos cargos conocidos de Aram Andrew Mangasarian.
Empresas | Cargo | Fin |
---|---|---|
ISOFOL MEDICAL AB | Director/Miembro de la Junta | 01/02/2023 |
EUROBIO SCIENTIFIC | Corporate Officer/Principal | - |
Exonhit
Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | Corporate Officer/Principal | - |
Caerus Consulting AS
Caerus Consulting AS Pharmaceuticals: MajorHealth Technology Caerus Consulting AS engages in the research and development in biotechnology. It develops antibiotics for life threatening bacterial diseases. Its technological core is chemistry on complex molecules. The company was founded by Torgeir Vaage on March 31, 2009 and is headquartered in Hovik, Norway. | Director/Miembro de la Junta | - |
Novexel SA
Novexel SA Pharmaceuticals: MajorHealth Technology Novexel SA researches and develops anti-infective drugs for the treatment of bacterial and fungal infections. The firm focuses on discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance. The company was founded in December 2004 and is headquartered in Romainville, France. | Corporate Officer/Principal | - |
Formación de Aram Andrew Mangasarian.
INSEAD | Masters Business Admin |
University of California San Diego | Doctorate Degree |
University of Wisconsin | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 3 |
---|---|
TME PHARMA N.V. | Health Technology |
EUROBIO SCIENTIFIC | Health Technology |
ISOFOL MEDICAL AB | Health Technology |
Empresas privadas | 5 |
---|---|
Novexel SA
Novexel SA Pharmaceuticals: MajorHealth Technology Novexel SA researches and develops anti-infective drugs for the treatment of bacterial and fungal infections. The firm focuses on discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance. The company was founded in December 2004 and is headquartered in Romainville, France. | Health Technology |
Exonhit
Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | Health Technology |
NOXXON Pharma AG
NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | Health Technology |
Caerus Consulting AS
Caerus Consulting AS Pharmaceuticals: MajorHealth Technology Caerus Consulting AS engages in the research and development in biotechnology. It develops antibiotics for life threatening bacterial diseases. Its technological core is chemistry on complex molecules. The company was founded by Torgeir Vaage on March 31, 2009 and is headquartered in Hovik, Norway. | Health Technology |
NOXXON Pharma NV Niederlassung Deutschland
NOXXON Pharma NV Niederlassung Deutschland BiotechnologyHealth Technology NOXXON Pharma NV Niederlassung Deutschland operates as a German biotechnology company. The private company is based in Berlin, Germany. | Health Technology |
- Bolsa de valores
- Insiders
- Aram Andrew Mangasarian